Table 1 General demographic and clinical data; mean ± SD and n (%)
Subjects | AS patients (n = 41) | Healthy controls (n = 10) | p-value |
|---|---|---|---|
Age (years) | 67 ± 9 | 62 ± 10 | 0.131 |
Male gender, n (%) | 21 (51%) | 5 (50%) | 0.945 |
Body mass index (kg/m2) | 28 ± 4.2 | 25 ± 3.6 | 0.029 |
BSA (m2) | 2 ± 0.24 | 2 ± 0.2 | 0.169 |
Duration between AVR and Visit 2 (d) | 125 ± 38 | – | – |
Prothesis data | |||
 Prosthesis size [mm] | 23 ± 2 | – | – |
 Biological prosthesis, n (%) | 39 (95%) | – | – |
 Prosthesis type Medtronic biological, n (%) | 1 (2%) | – | – |
 Prosthesis type Medtronic mechanical, n (%) | 1 (2%) | – | – |
 Prosthesis type Edwards, n (%) | 9 (22%) | – | – |
 Prosthesis type St Jude Medical Regent, n (%) | 1 (2%) | – | – |
 Prosthesis type Trifecta, n (%) | 21 (51%) | – | – |
 Prosthesis type CE Perimount Magna Ease, n (%) | 8 (20%) | – | – |
Risk factors | |||
 Bicuspid aortic valve, n(%) | 31 (76%) | 0 (0%) | < 0.001 |
 Dyslipidaemia, n(%) | 20 (49%) | 4 (40%) | 0.618 |
 Diabetes mellitus, n(%) | 4 (10%) | 1 (10%) | 0.981 |
 CCS III-VI, n(%) | 3 (7%) | 0 (0%) | 0.378 |
 NYHA III-VI, n(%) | 18 (35%) | 0 (0%) | 0.009 |
 Arterial hypertension, n(%) | 29 (71%) | 4 (40%) | 0.068 |
Medical treatment | |||
 Betablocker, n (%) | 17 (42%) | 3 (30%) | 0.506 |
 Calcium antagonist, n (%) | 4 (10%) | 1 (10%) | 0.981 |
 Diuretics, n (%) | 11 (27%) | 2 (20%) | 0.657 |
 ARB, n (%) | 9 (22%) | 2 (20%) | 0.893 |
 ACE-I, n (%) | 11 (29%) | 0 (0%) | 0.064 |